现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
9期
2147-2150
,共4页
胃间质瘤%复发%Fletcher分级%伊马替尼
胃間質瘤%複髮%Fletcher分級%伊馬替尼
위간질류%복발%Fletcher분급%이마체니
gastric gastrointestinal stromal tumors%recurrence%fletcher's classification%imatinib
目的：探讨胃间质瘤手术治疗后肿瘤复发及患者生存的影响因素。方法：对2006年1月至2012年6月新疆肿瘤医院收治的57例胃GIST患者临床病理和随访资料进行回顾性分析。结果：57例胃GIST患者中复发、转移10例（17．5％），主要发生部位为肝脏及腹腔。1年和3年无复发生存率分别是93％和84％。单因素分析显示，术后复发转移与核分裂象（＞5/50 HPF）、肿瘤直径（＞10cm）、Fletcher分级高有关；核分裂象（＞5/50 HPF）、复发转移与患者生存有关。结论：手术治疗是局部可切除原发GIST的标准治疗。Fletcher分级标准是评估 GIST 复发转移比较公认的指标。对于高危或复发转移胃GIST患者，建议服用伊马替尼治疗。
目的：探討胃間質瘤手術治療後腫瘤複髮及患者生存的影響因素。方法：對2006年1月至2012年6月新疆腫瘤醫院收治的57例胃GIST患者臨床病理和隨訪資料進行迴顧性分析。結果：57例胃GIST患者中複髮、轉移10例（17．5％），主要髮生部位為肝髒及腹腔。1年和3年無複髮生存率分彆是93％和84％。單因素分析顯示，術後複髮轉移與覈分裂象（＞5/50 HPF）、腫瘤直徑（＞10cm）、Fletcher分級高有關；覈分裂象（＞5/50 HPF）、複髮轉移與患者生存有關。結論：手術治療是跼部可切除原髮GIST的標準治療。Fletcher分級標準是評估 GIST 複髮轉移比較公認的指標。對于高危或複髮轉移胃GIST患者，建議服用伊馬替尼治療。
목적：탐토위간질류수술치료후종류복발급환자생존적영향인소。방법：대2006년1월지2012년6월신강종류의원수치적57례위GIST환자림상병리화수방자료진행회고성분석。결과：57례위GIST환자중복발、전이10례（17．5％），주요발생부위위간장급복강。1년화3년무복발생존솔분별시93％화84％。단인소분석현시，술후복발전이여핵분렬상（＞5/50 HPF）、종류직경（＞10cm）、Fletcher분급고유관；핵분렬상（＞5/50 HPF）、복발전이여환자생존유관。결론：수술치료시국부가절제원발GIST적표준치료。Fletcher분급표준시평고 GIST 복발전이비교공인적지표。대우고위혹복발전이위GIST환자，건의복용이마체니치료。
Objective:To analyze prognostic factors influencing tumor recurrence and survival after curative resec-tion of primary gastric GIST.Methods:The clinicopathological features of 57 cases with gastric GIST underwent surgi-cal resection between January 2006 and June 2012 at the Affiliated Tumor Hospital of Xinjiang Medical University were retrospectively reviewed.Clinical features and outcomes were analyzed.Results:Fifty-seven patients(31 males and 26 females)with a median age of 58 years(range,33 -76 years)were reviewed.Ten patients(17.5%)devel-oped tumor recurrence,the most common organs of recurrence were liver and intraperitoneal.The recurrence -free probability at 1 and 3 years were 93%and 84%respectively.Univariable analysis showed that mitotic count(>5/50 HPF),tumor size(>10cm)and Fletcher's classification high-risk were significant predictors of recurrence survival and that mitotic count(>5/50 HPF)and recurrence were significant prognostic factors.Conclusion:Surgical treat-ment remains the gold standard therapy for resectable GISTs.Fletcher's classification is the most important factor for predicting the recurrence or metastasis.Imatinib mesylate should be advocated for patients with high -risk gastric GIST or recurrence.
